Full-Time

Early detection medical lead

Autoimmune T1D

Posted on 11/18/2024

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

Biotechnology
Healthcare

Mid, Senior

Toronto, ON, Canada

Hybrid position.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • Healthcare degree (MD, PharmD, Pharmacist) or PhD relevant to the field of Specialty care/ Rare disease / Type 1 Diabetes
  • Previous experience in patient identification and data analytics desired
  • Industry experience in Medical Affairs > 2 years with proven experience managing & executing national strategy
  • Excellent interpersonal and communication skills, with ability to effectively engage internal and external stakeholders, build and cultivate strong working relationships
  • Excellent skills in influencing decision making
  • Used to working in matrix environment
  • Strong background in national health initiatives, or launching products requiring monitoring/screening
  • Experience in building partnerships with screening infrastructure players and in developing data-driven solutions, including AI to monitor and identify people at risk
  • Experience in product launch & launch excellence
  • Clear understanding of medical practice, clinical decision-making and healthcare systems related to patient care in Type I Diabetes or Immunology
  • Ability to leverage an omnichannel approach in the engagement with external experts to orchestrate a high-touch & personalized engagement based on their level of maturity and preferences
  • Knowledge of relevant healthcare systems, evolving medical landscape, regulatory and payer environment, public health, and industry trends
  • Strong communication and presentation skills in English both written and verbal.
Responsibilities
  • Adapting the Global medical people-at-risk screening, monitoring and infrastructure strategy and leading its execution at local level (e.g., coordinating all activities, internal and external stakeholders related to it) to help better identify people at-risk/patients
  • Mapping and evaluating the national/regional/local screening programs (completed, on-going, planned)
  • Facilitate country medical readiness to develop/support screening protocols, education, infra structure.
  • Lead local screening and monitoring strategy and programs leveraging partnerships and innovative techniques (advanced analytics, AI for people at risk profiling)
  • Identifying opportunities to improve screening and monitoring and infusion accessibility by identifying new testing channels and methodologies (e.g., via digital healthcare solutions), advocating for screening reimbursement (in collaboration with Market Access), deploying funding initiatives (e.g., sponsorship), demonstrating benefits and value proposition of screening (e.g., by developing local pilots, gathering data, and expanding them)
  • Co-designing a data-driven monitoring/registry strategy to identify and monitor patients progressing through different stages of T1D and / or people at risk of T1D.
  • Establishing comprehensive medical education/scientific content creation around assessing the risk of type 1 diabetes, screening for Type 1 diabetes with autoantibody testing and monitoring those with positive antibodies
  • Driving strategic partnerships with KOL/DOL/societies related to screening
  • Co-creating screening/monitoring tools together with KOLs and scientific societies/organizations driving the screening activities.
  • Ensuring strict compliance and validating any screening and monitoring partnerships brough by cross-functional team, incl. diagnostic companies (to e.g., ensure testing accessibility and standardization where relevant), electronic medical record companies & other sources of data (to e.g., inform sophisticated people at risk profiling, insights generation, monitoring), telemedicine platforms etc.
  • Collaborating with Patient Experience to inform the end-to-end patient journey development.
  • Coordinating and working closely with the field medical teams on the implementation of the end-to-end patient / person-at-risk journey, from person-at-risk identification to infusion readiness.

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline and a global presence. The company's goal is to enhance health outcomes and improve the quality of life for individuals worldwide.

Company Stage

Grant

Total Funding

$2B

Headquarters

Paris, France

Founded

N/A

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's strong financial performance, as evidenced by its raised 2024 outlook, indicates robust growth and stability.
  • The company's strategic investments in innovative biotech firms, such as Ventyx Biosciences, enhance its pipeline and potential for breakthrough therapies.
  • Sanofi's Dupixent receiving a positive recommendation for expanded use in children demonstrates its leadership in addressing unmet medical needs.

What critics are saying

  • The highly competitive pharmaceutical market requires Sanofi to continuously innovate to maintain its market position.
  • Regulatory challenges in different regions could delay product approvals and impact revenue streams.

What makes Sanofi unique

  • Sanofi's extensive R&D efforts and strategic partnerships, such as with Orano Med for radioligand therapies, set it apart in the competitive pharmaceutical landscape.
  • The company's global reach and focus on patient-centric solutions allow it to effectively navigate diverse regulatory environments and deliver innovative treatments worldwide.
  • Sanofi's investment in sustainable initiatives, like SureChill's 'Cooling as a Service' model, highlights its commitment to addressing healthcare challenges in emerging markets.

Help us improve and share your feedback! Did you find this helpful?